New adjuvant/delivery strategies that could enable protein and peptide vaccines to elicit both potent cellular and humoral immunity would be highly complementary to existing approaches in HIV vaccine development. In this Core, we will supply and further develop two classes of potent novel adjuvants recently developed in the Irvine lab to support the subunit vaccine studies of projects 1 and 2 in studying human immune responses to HIV immunogens in BLT humanized mice: stabilized lipid nanocapsules (SLNCs) and membrane-targeted micelles (MTMs). SLNCs are a lipid nanocapsule system for delivery of protein or peptide antigens together with molecular danger signals such as TLR agonists (TLRa), which retain entrapped antigen/TLRa much more effectively than traditional liposomes, leading to enhanced antigen/adjuvant delivery to dendritic cells and sustained accumulation of antigen in draining lymph nodes following vaccination. The second adjuvant system, membrane-targeted micelles (MTM), is based on the conjugation of molecular adjuvants or peptide antigen cargos to a micelle-forming lipid tail. These amphiphilic molecules self-assemble to form nanoparticles -15 nm in diameter in water, but also dynamically dis-assemble to anchor their lipid tails in the membrane on contact with cells. MTMs dramatically target TLRa or peptides to lymph nodes, forming intranodal vaccine depots following s.c. injection, and driving strongly enhanced immune responses to co-administered protein antigens. We will provide these potent adjuvants on demand for BLT humanized mouse immunization studies for projects 1 and 2. In addition, we will further develop these adjuvants to maximize the effectiveness in BLT mice while designing for negligible toxicity/reactogenicity, to ensure their relevance for human vaccine development. Results from these studies will further the BLT humanized mouse model as a tool for vaccine development, by identifying effective adjuvants and routes of administration for vaccine delivery, and provide new adjuvants applicable to diverse subunit vaccines beyond HIV.
The development of novel vaccine adjuvants for promoting humoral and cellular responses is a pressing need for HIV vaccine development. This Core will both provide and develop novel adjuvants that support the studies of HIV vaccines in humanized mice of projects 1 and 2, which may be broadly applicable to human vaccines.
|Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527|
|Martins, Mauricio A; Tully, Damien C; Pedreño-Lopez, Núria et al. (2018) Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication. J Virol 92:|
|Tully, Damien C; Claiborne, Daniel T; Allen, Todd M (2017) Interferon-I: The Pièce de Résistance of HIV-1 Transmission? Trends Microbiol 25:332-334|
|Ranasinghe, Srinika; Lamothe, Pedro A; Soghoian, Damien Z et al. (2016) Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion. Immunity 45:917-930|
|Deruaz, Maud; Moldt, Brian; Le, Khoa M et al. (2016) Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. J Infect Dis 214:612-6|
|Tully, Damien C; Ogilvie, Colin B; Batorsky, Rebecca E et al. (2016) Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog 12:e1005619|
|Garcia-Beltran, Wilfredo F; Hölzemer, Angelique; Martrus, Gloria et al. (2016) Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat Immunol 17:1067-74|
|Moyer, Tyson J; Zmolek, Andrew C; Irvine, Darrell J (2016) Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest 126:799-808|
|Liu, Haipeng; Irvine, Darrell J (2015) Guiding principles in the design of molecular bioconjugates for vaccine applications. Bioconjug Chem 26:791-801|
|Altfeld, Marcus; Gale Jr, Michael (2015) Innate immunity against HIV-1 infection. Nat Immunol 16:554-62|
Showing the most recent 10 out of 21 publications